UNSPSC 51282505: Cefaloridine or cephaloridine

This classification denotes a cephalosporin antibiotic with the molecular formula C19H17N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LVZ1VC61HB, chemically known as pyridinium, 1-((2-carboxy-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, (6r-trans)- but generally known as cefaloridine, which bears US NIH Compound Identifier 5773. European Medicines Agency schedules Cefaloridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06169MIG.

UNSPSC 51282505 Cefaloridine or cephaloridine is a Commodity code that nominally addresses a specific antibiotic pharmaceutical, but the recent state and local activity tagged to this code shows little alignment with that scope. The two recorded opportunities involve unrelated pharmaceutical products: one procurement covers antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) through a piggyback warehouse contract, and the other addresses opioid-reversal agents and drug deactivation systems. Neither product matches the code's stated pharmaceutical family. State and local health departments and counties are the issuing bodies recorded under this code, but the disconnect between the code designation and the actual goods being procured suggests either a cataloging error or inconsistent application of UNSPSC taxonomy to pharmaceutical purchases at the state and local level.

The recorded activity spans Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets on August 28, 2026 (an already-completed award under an Invitation for Bid process, not an open solicitation). Seminole County, Florida, posted an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, with a response deadline of July 26, 2023 (a past-due opportunity). The code shows minimal recent activity under its stated scope, and firms should verify whether opportunities tagged to this code represent genuine pharmaceutical supply needs in their target jurisdictions or reflect upstream classification gaps in state and local procurement systems.